Format
Items per page
Sort by

Send to:

Choose Destination

Results: 19

1.

OCT angiography and sequential quantitative analysis of type 2 neovascularization after ranibizumab therapy.

Kuehlewein L, Sadda SR, Sarraf D.

Eye (Lond). 2015 May 15. doi: 10.1038/eye.2015.80. [Epub ahead of print]

PMID:
25976641
2.

[Intraocular pressure and ocular blood flow features intravitreal infection of anti-vascular endothelial growth factor agents].

Mamikonian VR, Galoian NS, Budzinskaia MV, Kazarian ÉÉ, Sdobnikova SV, Shmeleva-Demir OA, Rafaeian AA, Ryzhkova EG.

Vestn Oftalmol. 2014 Sep-Oct;130(5):16-21. Russian.

PMID:
25711057
3.

Interleukin-18 has antipermeablity and antiangiogenic activities in the eye: reciprocal suppression with VEGF.

Shen J, Choy DF, Yoshida T, Iwase T, Hafiz G, Xie B, Hackett SF, Arron JR, Campochiaro PA.

J Cell Physiol. 2014 Aug;229(8):974-83. doi: 10.1002/jcp.24575.

PMID:
24515951
4.

[Editor's commentary].

Süveges I.

Orv Hetil. 2013 Nov 10;154(45):1771-2. doi: 10.1556/OH.2013.29747. Hungarian. No abstract available.

PMID:
24184928
5.

Can intravitreal ranibizumab alter retrobulbar circulation in eyes with age-related macular degeneration?

Yuksel K, Altinkaynak H, Kina A, Kara N, Yazici AT, Demirok A.

J Ocul Pharmacol Ther. 2013 Oct;29(8):723-7. doi: 10.1089/jop.2013.0051. Epub 2013 Jul 5.

PMID:
23829173
6.

Noninvasive investigation of deep vascular pathologies of exudative macular diseases by high-penetration optical coherence angiography.

Hong YJ, Miura M, Makita S, Ju MJ, Lee BH, Iwasaki T, Yasuno Y.

Invest Ophthalmol Vis Sci. 2013 May 1;54(5):3621-31. doi: 10.1167/iovs.12-11184.

PMID:
23633664
7.

Intravitreal aflibercept for neovascular age-related macular degeneration.

Xu D, Kaiser PK.

Immunotherapy. 2013 Feb;5(2):121-30. doi: 10.2217/imt.12.158.

PMID:
23413903
8.

A safety review and meta-analyses of bevacizumab and ranibizumab: off-label versus goldstandard.

Schmucker C, Ehlken C, Agostini HT, Antes G, Ruecker G, Lelgemann M, Loke YK.

PLoS One. 2012;7(8):e42701. doi: 10.1371/journal.pone.0042701. Epub 2012 Aug 3. Review.

9.

Short-term impact of intravitreal ranibizumab injection on axial ocular dimension and intraocular pressure.

Goktas A, Goktas S, Atas M, Demircan S, Yurtsever Y.

Cutan Ocul Toxicol. 2013 Mar;32(1):23-6. doi: 10.3109/15569527.2012.696569. Epub 2012 Jun 27.

PMID:
22737998
10.

The expanding role of vascular endothelial growth factor inhibitors in ophthalmology.

Stewart MW.

Mayo Clin Proc. 2012 Jan;87(1):77-88. doi: 10.1016/j.mayocp.2011.10.001. Review.

11.

Does ranibizumab (Lucentis®) change retrobulbar blood flow in patients with neovascular age-related macular degeneration?

Mete A, Saygili O, Mete A, Gungor K, Bayram M, Bekir N.

Ophthalmic Res. 2012;47(3):141-5. doi: 10.1159/000330509. Epub 2011 Oct 26.

PMID:
22042133
12.

Systemic and ocular safety of intravitreal anti-VEGF therapies for ocular neovascular disease.

Tolentino M.

Surv Ophthalmol. 2011 Mar-Apr;56(2):95-113. doi: 10.1016/j.survophthal.2010.08.006. Review.

PMID:
21335144
13.

Bevacizumab in ophthalmology: the controversy moves forward.

Gillies MC.

Clin Experiment Ophthalmol. 2010 May;38(4):333-4. doi: 10.1111/j.1442-9071.2010.02300.x. No abstract available.

PMID:
20642588
14.

Neovascular age-related macular degeneration: decision making and optimal management.

Harding SP.

Eye (Lond). 2010 Mar;24(3):497-505. doi: 10.1038/eye.2009.316. Epub 2010 Jan 8. Review.

PMID:
20057511
15.

Identifying early recurrence of choroidal neovascularization during treatment with ranibizumab using C-scan.

Siqueira RC, Nogueira MC.

Eur J Ophthalmol. 2010 May-Jun;20(3):559-64.

PMID:
20037904
16.

Anti-vascular endothelial growth factor therapy for neovascular ocular diseases other than age-related macular degeneration.

Ciulla TA, Rosenfeld PJ.

Curr Opin Ophthalmol. 2009 May;20(3):166-74. doi: 10.1097/ICU.0b013e328329d173. Review.

PMID:
19381089
17.
18.

In vivo three-dimensional imaging of neovascular age-related macular degeneration using optical frequency domain imaging at 1050 nm.

de Bruin DM, Burnes DL, Loewenstein J, Chen Y, Chang S, Chen TC, Esmaili DD, de Boer JF.

Invest Ophthalmol Vis Sci. 2008 Oct;49(10):4545-52. doi: 10.1167/iovs.07-1553. Epub 2008 Apr 4.

PMID:
18390638
19.

Anti-vascular endothelial growth factor therapy for ocular neovascular disease.

Andreoli CM, Miller JW.

Curr Opin Ophthalmol. 2007 Nov;18(6):502-8. Review.

PMID:
18163003
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk